Literature DB >> 26484636

Reproductive Planning and Contraception for Women with Inflammatory Bowel Diseases.

Lori M Gawron1, Jessica Sanders, Katelyn P Steele, Ann D Flynn.   

Abstract

Women with chronic medical conditions, such as inflammatory bowel diseases, are at increased risk for adverse pregnancy outcomes. Pregnancy outcomes for these conditions are best during stable disease remission. Unfortunately, women with inflammatory bowel disease are equally as likely as the general population to have unintended pregnancies. Patients look to their gastroenterologist for contraceptive counseling; however, the current standards for disease management do not prioritize this topic. Guidelines based on available evidence and expert opinion, such as the Centers for Disease Control U.S. Medical Eligibility Criteria for Contraceptive Use, exist to help practitioners provide safe and effective contraception to women with chronic medical conditions. If health care providers were to educate themselves and screen women with inflammatory bowel disease for risk of unintended pregnancy, there would be a reduction in the number of unintended pregnancies and subsequent adverse neonatal and maternal outcomes.

Entities:  

Mesh:

Year:  2016        PMID: 26484636      PMCID: PMC6861010          DOI: 10.1097/MIB.0000000000000606

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  72 in total

Review 1.  Systematic review: fertility in non-surgically treated inflammatory bowel disease.

Authors:  N Tavernier; M Fumery; L Peyrin-Biroulet; J-F Colombel; C Gower-Rousseau
Journal:  Aliment Pharmacol Ther       Date:  2013-09-04       Impact factor: 8.171

2.  Disease-related pregnancy concerns and reproductive planning in women with inflammatory bowel diseases.

Authors:  Lori M Gawron; Adina R Goldberger; Andrew J Gawron; Cassing Hammond; Laurie Keefer
Journal:  J Fam Plann Reprod Health Care       Date:  2015-04-22

3.  The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.

Authors:  C N Bernstein; J F Blanchard; D S Houston; A Wajda
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

4.  The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy.

Authors:  S F Grimmer; D J Back; M L Orme; A Cowie; I Gilmore; J Tjia
Journal:  Contraception       Date:  1986-01       Impact factor: 3.375

5.  Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study.

Authors:  B A Lashner; S V Kane; S B Hanauer
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

6.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.

Authors:  Jürgen C Dinger; Lothar A J Heinemann; Dörthe Kühl-Habich
Journal:  Contraception       Date:  2007-02-23       Impact factor: 3.375

7.  Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

Authors:  A Timmer; L R Sutherland; F Martin
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

8.  Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions.

Authors:  Réme Mountifield; Peter Bampton; Ruth Prosser; Kate Muller; Jane M Andrews
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 9.  Oral contraceptives for pain associated with endometriosis.

Authors:  L Davis; S S Kennedy; J Moore; A Prentice
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 10.  Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies.

Authors:  Mathurin Fumery; Cao Xiaocang; Luc Dauchet; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2013-10-30       Impact factor: 9.071

View more
  2 in total

1.  Contraceptive Use in Women With Inflammatory Bowel Disease.

Authors:  Lori M Gawron
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

2.  The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: A systematic review and meta-analysis.

Authors:  Yeon Hee Kim; Birgit Pfaller; Alanna Marson; Hyeon Woo Yim; Vivian Huang; Shinya Ito
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.